Internationaal Verdrag tegen doping in de sport

International Convention Against Doping in Sport

Preamble

The General Conference of the United Nations Educational, Scientific and Cultural Organization, hereinafter referred to as UNESCO, meeting in Paris from 3 to 21 October 2005, at its 33rd session,

Considering that the aim of UNESCO is to contribute to peace and security by promoting collaboration among nations through education, science and culture,

Referring to existing international instruments relating to human rights,

Aware of resolution 58/5 adopted by the General Assembly of the United Nations on 3 November 2003, concerning sport as a means to promote education, health, development and peace, notably its paragraph 7,

Conscious that sport should play an important role in the protection of health, in moral, cultural and physical education and in promoting international understanding and peace,

Noting the need to encourage and coordinate international cooperation towards the elimination of doping in sport,

Concerned by the use of doping by athletes in sport and the consequences thereof for their health, the principle of fair play, the elimination of cheating and the future of sport,

Mindful that doping puts at risk the ethical principles and educational values embodied in the International Charter of Physical Education and Sport of UNESCO and in the Olympic Charter,

Recalling that the Anti-Doping Convention and its Additional Protocol adopted within the framework of the Council of Europe are the public international law tools, which are at the origin of national anti-doping policies and of intergovernmental cooperation,

Recalling the Recommendations on doping adopted by the second, third and fourth International Conferences of Ministers and Senior Officials responsible for Physical Education and Sport organized by UNESCO at Moscow (1988), Punta del Este (1999) and Athens (2004) and 32 C/Resolution 9 adopted by the General Conference of UNESCO at its 32nd session (2003),

Bearing in mind the World Anti-Doping Code adopted by the World Anti-Doping Agency at the World Conference on Doping in Sport, Copenhagen, 5 March 2003 and the Copenhagen Declaration on Anti-Doping in Sport,

Mindful also of the influence that elite athletes have on youth,

Aware of the ongoing need to conduct and promote research with the objectives of improving detection of doping and better understanding of the factors affecting use in order for prevention strategies to be most effective,

Aware also of the importance of ongoing education of athletes, athlete support personnel and the community at large in preventing doping,

Mindful of the need to build the capacity of States Parties to implement anti-doping programmes,

Aware that public authorities and the organizations responsible for sport have complementary responsibilities to prevent and combat doping in sport, notably to ensure the proper conduct, on the basis of the principle of fair play, of sports events and to protect the health of those that take part in them,

Recognizing that these authorities and organizations must work together for these purposes ensuring the highest degree of independence and transparency at all appropriate levels,

Determined to take further and stronger cooperative action aimed at the elimination of doping in sport,

Recognizing that the elimination of doping in sport is dependent in part upon progressive harmonization of anti-doping standards and practices in sport and cooperation at the national and global levels,

Adopts this Convention on this nineteenth day of October 2005.

PART

I

SCOPE

Article

1

Purpose of the Convention

The purpose of this Convention, within the framework of the strategy and programme of activities of UNESCO in the area of physical education and sport, is to promote the prevention of and the fight against doping in sport, with a view to its elimination.

Article

2

Definitions

These definitions are to be understood within the context of the World Anti-Doping Code. However, in case of conflict the provisions of the Convention will prevail.

For the purposes of this Convention:

  • 1.

    “Accredited doping control laboratories” means laboratories accredited by the World Anti-Doping Agency.

  • 2.

    “Anti-doping organization” means an entity that is responsible for adopting rules for initiating, implementing or enforcing any part of the doping control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other major event organizations that conduct testing at their events, the World Anti-Doping Agency, international federations, and national anti-doping organizations.

  • 3.

    “Anti-doping rule violation” in sport means one or more of the following:

    • a)

      the presence of a prohibited substance or its metabolites or markers in an athlete’s bodily specimen;

    • b)

      use or attempted use of a prohibited substance or a prohibited method;

    • c)

      refusing, or failing without compelling justification, to submit to sample collection after notification as authorized in applicable anti-doping rules or otherwise evading sample collection;

    • d)

      violation of applicable requirements regarding athlete availability for out-of-competition testing including failure to provide required whereabouts information and missed tests which are declared based on reasonable rules;

    • e)

      tampering, or attempting to tamper, with any part of doping control;

    • f)

      possession of prohibited substances or methods;

    • g)

      trafficking in any prohibited substance or prohibited method;

    • h)

      administration or attempted administration of a prohibited substance or prohibited method to any athlete, or assisting, encouraging, aiding, abetting, covering up or any other type of complicity involving an anti-doping rule violation or any attempted violation.

  • 4.

    “Athlete” means, for the purposes of doping control, any person who participates in sport at the international or national level as defined by each national anti-doping organization and accepted by States Parties and any additional person who participates in a sport or event at a lower level accepted by States Parties. For the purposes of education and training programmes, “athlete” means any person who participates in sport under the authority of a sports organization.

  • 5.

    “Athlete support personnel” means any coach, trainer, manager, agent, team staff, official, medical or paramedical personnel working with or treating athletes participating in or preparing for sports competition.

  • 6.

    “Code” means the World Anti-Doping Code adopted by the World Anti-Doping Agency on 5 March 2003 at Copenhagen which is attached as Appendix 1 to this Convention.

  • 7.

    “Competition” means a single race, match, game or singular athletic contest.

  • 8.

    “Doping control” means the process including test distribution planning, sample collection and handling, laboratory analysis, results management, hearings and appeals.

  • 9.

    “Doping in sport” means the occurrence of an anti-doping rule violation

  • 10.

    “Duly authorized doping control teams” means doping control teams operating under the authority of international or national anti-doping organizations.

  • 11.

    “In-competition” testing means, for purposes of differentiating between in-competition and out-of-competition testing, unless provided otherwise in the rules of an international federation or other relevant anti-doping organization, a test where an athlete is selected for testing in connection with a specific competition.

  • 12.

    “International Standard for Laboratories” means the standard which is attached as Appendix 2 to this Convention

  • 13.

    “International Standard for Testing” means the standard which is attached as Appendix 3 to this Convention.

  • 14.

    “No advance notice” means a doping control which takes place with no advance warning to the athlete and where the athlete is continuously chaperoned from the moment of notification through sample provision.

  • 15.

    “Olympic Movement” means all those who agree to be guided by the Olympic Charter and who recognize the authority of the International Olympic Committee, namely: the international federations of sports on the programme of the Olympic Games; the National Olympic Committees, the Organizing Committees of the Olympic Games, athletes, judges and referees, associations and clubs, as well as all the organizations and institutions recognized by the International Olympic Committee.

  • 16.

    “Out-of-competition” doping control means any doping control which is not conducted in competition.

  • 17.

    “Prohibited List” means the list which appears in Annex I to this Convention identifying the prohibited substances and prohibited methods.

  • 18.

    “Prohibited method” means any method so described on the Prohibited List, which appears in Annex I to this Convention.

  • 19.

    “Prohibited substance” means any substance so described on the Prohibited List, which appears in Annex I to this Convention.

  • 20.

    “Sports organization” means any organization that serves as the ruling body for an event for one or several sports.

  • 21.

    “Standards for Granting Therapeutic Use Exemptions” means those standards that appear in Annex II to this Convention.

  • 22.

    “Testing” means the parts of the doping control process involving test distribution planning, sample collection, sample handling, and sample transport to the laboratory.

  • 23.

    “Therapeutic use exemption” means an exemption granted in accordance with Standards for Granting Therapeutic Use Exemptions.

  • 24.

    “Use” means the application, ingestion, injection or consumption by any means whatsoever of any prohibited substance or prohibited method.

  • 25.

    “World Anti-Doping Agency (WADA)” means the foundation so named established under Swiss law on 10 November 1999.

Article

3

Means to achieve the purpose of the Convention

In order to achieve the purpose of the Convention, States Parties undertake to:

  • a.

    adopt appropriate measures at the national and international levels which are consistent with the principles of the Code;

  • b.

    encourage all forms of international cooperation aimed at protecting athletes and ethics in sport, and at sharing the results of research;

  • c.

    foster international cooperation between States Parties and leading organizations in the fight against doping in sport, in particular with the World Anti-Doping Agency.

Article

4

Relationship of the Convention to the Code

Article

5

Measures to achieve the objectives of the Convention

In abiding by the obligations contained in this Convention, each State Party undertakes to adopt appropriate measures. Such measures may include legislation, regulation, policies or administrative practices.

Article

6

Relationship to other international instruments

This Convention shall not alter the rights and obligations of States Parties which arise from other agreements previously concluded and consistent with the object and purpose of this Convention. This does not affect the enjoyment by other States Parties of their rights or the performance of their obligations under this Convention.

PART

II

ANTI-DOPING ACTIVITIES AT THE NATIONAL LEVEL

Article

7

Domestic coordination

States Parties shall ensure the application of the present Convention, notably through domestic coordination. To meet their obligations under this Convention, States Parties may rely on anti-doping organizations as well as sports authorities and organizations.

Article

8

Restricting the availability and use in sport of prohibited substances and methods

Article

9

Measures against athlete support personnel

States Parties shall themselves take measures or encourage sports organizations and anti-doping organizations to adopt measures, including sanctions or penalties, aimed at athlete support personnel who commit an anti-doping rule violation or other offence connected with doping in sport.

Article

10

Nutritional supplements

States Parties, where appropriate, shall encourage producers and distributors of nutritional supplements to establish best practices in the marketing and distribution of nutritional supplements, including information regarding their analytic composition and quality assurance.

Article

11

Financial measures

States Parties shall, where appropriate:

  • a)

    provide funding within their respective budgets to support a national testing programme across all sports or assist sports organizations and anti-doping organizations in financing doping controls either by direct subsidies or grants, or by recognizing the costs of such controls when determining the overall subsidies or grants to be awarded to those organizations;

  • b)

    take steps to withhold sport-related financial support to individual athletes or athlete support personnel who have been suspended following an anti-doping rule violation, during the period of their suspension;

  • c)

    withhold some or all financial or other sport-related support from any sports organization or anti-doping organization not in compliance with the Code or applicable anti-doping rules adopted pursuant to the Code.

Article

12

Measures to facilitate doping control

States Parties shall, where appropriate:

  • a)

    encourage and facilitate the implementation by sports organizations and anti-doping organizations within their jurisdiction of doping controls in a manner consistent with the Code including no-advance notice, out-of-competition and in-competition testing;

  • b)

    encourage and facilitate the negotiation by sports organizations and anti-doping organizations of agreements permitting their members to be tested by duly authorized doping control teams from other countries;

  • c)

    undertake to assist the sports organizations and anti-doping organizations within their jurisdiction in gaining access to an accredited doping control laboratory for the purposes of doping control analysis.

PART

III

INTERNATIONAL COOPERATION

Article

13

Cooperation between anti-doping organizations and sports organizations

States Parties shall encourage cooperation between anti-doping organizations, public authorities, and sports organizations within their jurisdiction and those within the jurisdiction of other States Parties in order to achieve, at the international level, the purpose of this Convention.

Article

14

Supporting the mission of the World Anti-Doping Agency

States Parties undertake to support the important mission of the World Anti-Doping Agency in the international fight against doping.

Article

15

Equal funding of the World Anti-Doping Agency

States Parties support the principle of equal funding of the World Anti-Doping Agency’s approved annual core budget by public authorities and the Olympic Movement.

Article

16

International cooperation in doping control

Recognizing that the fight against doping in sport can only be effective when athletes can be tested with no advance notice and samples can be transported in a timely manner to laboratories for analysis, States Parties shall, where appropriate and in accordance with domestic law and procedures:

  • a)

    facilitate the task of the World Anti-Doping Agency and anti-doping organizations operating in compliance with the Code, subject to relevant host countries’ regulations, of conducting in- or out-of-competition doping controls on their athletes, whether on their territory or elsewhere;

  • b)

    facilitate the timely movement of duly authorized doping control teams across borders when conducting doping control activities;

  • c)

    cooperate to expedite the timely shipping or carrying across borders of samples in such a way as to maintain their security and integrity;

  • d)

    assist in the international coordination of doping controls by various anti-doping organizations, and cooperate to this end with the World Anti-Doping Agency;

  • e)

    promote cooperation between doping control laboratories within their jurisdiction and those within the jurisdiction of other States Parties. In particular, States Parties with accredited doping control laboratories should encourage laboratories within their jurisdiction to assist other States Parties in enabling them to acquire the experience, skills and techniques necessary to establish their own laboratories should they wish to do so;

  • f)

    encourage and support reciprocal testing arrangements between designated anti-doping organizations, in conformity with the Code;

  • g)

    mutually recognize the doping control procedures and test results management, including the sport sanctions thereof, of any anti-doping organization that are consistent with the Code.

Article

17

Voluntary Fund

Article

18

Use and governance of the Voluntary Fund

Resources in the Voluntary Fund shall be allocated by the Conference of Parties for the financing of activities approved by it, notably to assist States Parties in developing and implementing anti-doping programmes, in accordance with the provisions of this Convention, taking into consideration the goals of the World Anti-Doping Agency, and may serve to cover functioning costs of this Convention. No political, economic or other conditions may be attached to contributions made to the Voluntary Fund.

PART

IV

EDUCATION AND TRAINING

Article

19

General education and training principles

Article

20

Professional codes of conduct

States Parties shall encourage relevant competent professional associations and institutions to develop and implement appropriate codes of conduct, good practice and ethics related to anti-doping in sport that are consistent with the Code.

Article

21

Involvement of athletes and athlete support personnel

States Parties shall promote and, within their means, support active participation by athletes and athlete support personnel in all facets of the anti-doping work of sports and other relevant organizations and encourage sports organizations within their jurisdiction to do likewise.

Article

22

Sports organizations and ongoing education and training on anti-doping

States Parties shall encourage sports organizations and anti-doping organizations to implement ongoing education and training programmes for all athletes and athlete support personnel on the subjects identified in Article 19.

Article

23

Cooperation in education and training

States Parties shall cooperate mutually and with the relevant organizations to share, where appropriate, information, expertise and experience on effective anti-doping programmes.

PART

V

RESEARCH

Article

24

Promotion of research in anti-doping

States Parties undertake, within their means, to encourage and promote anti-doping research in cooperation with sports and other relevant organizations on:

  • a)

    prevention, detection methods, behavioural and social aspects, and the health consequences of doping;

  • b)

    ways and means of devising scientifically-based physiological and psychological training programmes respectful of the integrity of the person;

  • c)

    the use of all emerging substances and methods resulting from scientific developments.

Article

25

Nature of anti-doping research

When promoting anti-doping research, as set out in Article 24, States Parties shall ensure that such research will:

  • a)

    comply with internationally recognized ethical practices;

  • b)

    avoid the administration to athletes of prohibited substances and methods;

  • c)

    be undertaken only with adequate precautions in place to prevent the results of anti-doping research being misused and applied for doping.

Article

26

Sharing the results of anti-doping research

Subject to compliance with applicable national and international law, States Parties shall, where appropriate, share the results of available anti-doping research with other States Parties and the World Anti-Doping Agency.

Article

27

Sport science research

States Parties shall encourage:

  • a)

    members of the scientific and medical communities to carry out sport science research in accordance with the principles of the Code;

  • b)

    sports organizations and athlete support personnel within their jurisdiction to implement sport science research that is consistent with the principles of the Code.

PART

VI

MONITORING OF THE CONVENTION

Article

28

Conference of Parties

Article

29

Advisory organization and observers to the Conference of Parties

The World Anti-Doping Agency shall be invited as an advisory organization to the Conference of Parties. The International Olympic Committee, the International Paralympic Committee, the Council of Europe, and the Intergovernmental Committee for Physical Education and Sport (CIGEPS) shall be invited as observers. The Conference of Parties may decide to invite other relevant organizations as observers.

Article

30

Functions of the Conference of Parties

Article

31

National reports to the Conference of Parties

States Parties shall forward every two years to the Conference of Parties through the Secretariat, in one of the official languages of UNESCO, all relevant information concerning measures taken by them for the purpose of complying with the provisions of this Convention.

Article

32

Secretariat of the Conference of Parties

Article

33

Amendments

Article

34

Specific amendment procedure for the Annexes to the Convention

PART

VII

FINAL CLAUSES

Article

35

Federal or non-unitary constitutional systems

The following provisions shall apply to States Parties that have a federal or non-unitary constitutional system:

  • a)

    With regard to the provisions of this Convention, the implementation of which comes under the legal jurisdiction of the federal or central legislative power, the obligations of the federal or central government shall be the same as for those States Parties which are not federal States;

  • b)

    With regard to the provisions of this Convention, the implementation of which comes under the jurisdiction of individual constituent States, countries, provinces or cantons which are not obliged by the constitutional system of the federation to take legislative measures, the federal government shall inform the competent authorities of such States, countries, provinces or cantons of the said provisions, with its recommendation for their adoption.

Article

36

Ratification, acceptance, approval or accession

This Convention shall be subject to ratification, acceptance, approval or accession by States Members of UNESCO in accordance with their respective constitutional procedures. The instruments of ratification, acceptance, approval or accession shall be deposited with the Director-General of UNESCO.

Article

37

Entry into force

Article

38

Territorial extension of the Convention

Article

39

Denunciation

Any State Party may denounce this Convention. The denunciation shall be notified by an instrument in writing, deposited with the Director-General of UNESCO. The denunciation shall take effect on the first day of the month following the expiration of a period of six months after the receipt of the instrument of denunciation. It shall in no way affect the financial obligations of the State Party concerned until the date on which the withdrawal takes effect.

Article

40

Depositary

The Director-General of UNESCO shall be the Depositary of this Convention and amendments thereto. As the Depositary, the Director-General of UNESCO shall inform the States Parties to this Convention, as well as the other States Members of the Organization of:

  • a)

    the deposit of any instrument of ratification, acceptance, approval or accession;

  • b)

    the date of entry into force of this Convention in accordance with Article 37;

  • c)

    any report prepared in pursuance of the provisions of Article 31;

  • d)

    any amendment to the Convention or to the Annexes adopted in accordance with Articles 33 and 34 and the date on which the amendment comes into force;

  • e)

    any declaration or notification made under the provisions of Article 38;

  • f)

    any notification made under the provisions of Article 39 and the date on which the denunciation takes effect;

  • g)

    any other act, notification or communication relating to this Convention.

Article

42

Authoritative texts

Article

43

Reservations

No reservations that are incompatible with the object and purpose of the present Convention shall be permitted.

DONE in Paris, this nineteenth day of October 2005, in two authentic copies bearing the signature of the President of the General Conference of UNESCO at its 33rd session and of the Director-General of UNESCO, which shall be deposited in the archives of UNESCO.

Annex

I

The 2006 prohibited List World Anti-Doping Code

The use of any drug should be limited to medically justified indications

All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4 and S6.a, and Prohibited Methods M1, M2 and M3.

Substances and methods prohibited at all times (in- and out-of-competition)

Prohibited substances

S1. Anabolic agents

Anabolic agents are prohibited.

  • 1.

    Anabolic Androgenic Steroids (AAS)

    • a.

      Exogenous1)For purposes of this section:“exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.* AAS, including:

      1-androstendiol (5α-androst-1-ene-3β,17β-diol); 1-androstendione (5α-androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s).

    • b.

      Endogenous2)For purposes of this section:“endogenous” refers to a substance which is capable of being produced by the body naturally. AAS when administered exogenously:

      androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:

      5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19-noretiocholanolone.

    [Comment to class S1.1b:

    Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance and an Adverse Analytical Finding will be reported where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiological or pathological condition.

    In all cases, and at any concentration, the Athlete’s Sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary.

    When a value does not so deviate from the range of values normally found in humans and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s).

    When such further investigation is required the result shall be reported by the laboratory as atypical and not as adverse. If a laboratory reports, using an additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary, and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied, and the minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing three no-advance notice tests in a period of three months by the relevant Anti-Doping Organization. The result that triggered this longitudinal study shall be reported as atypical. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall then be reported as an Adverse Analytical Finding.

    In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent test(s).

    For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance. In such case, no further investigation is necessary.

    Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance.]

  • 2.

    Other Anabolic Agents, including but not limited to:

    Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

For the purposes of this section:

* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.

** “endogenous” refers to a substance which is capable of being produced by the body naturally.

S2. Hormones and related substances

The following substances and their releasing factors, are prohibited:

  • 1.

    Erythropoiesis-Stimulating Agents (e.g. erythropoietin (EPO), darbepoietin (dEPO), hematide);

  • 2.

    Growth Hormone (GH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs);

  • 3.

    Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH), prohibited in males only;

  • 4.

    Insulins;

  • 5.

    Corticotrophins;

    and other substances with similar chemical structure or similar biological effect(s).

[Comment to class S2:

Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample satisfies positivity criteria established by WADA or otherwise so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production.

If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding.]

S3. Beta-2 agonists

All beta-2 agonists including their D- and L-isomers are prohibited.

Therefore, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation also require a Therapeutic Use Exemption in accordance with the relevant section of the International Standard for Therapeutic Use Exemptions.

Despite the granting of any form of Therapeutic Use Exemption, the presence of salbutamol in urine in excess of 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose of inhaled salbutamol.

S4. Hormones antagonists and modulators

The following classes are prohibited:

  • 1.

    Aromatase inhibitors including, but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone.

  • 2.

    Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.

  • 3.

    Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.

  • 4.

    Agents modifying myostatin function(s) including, but not limited to: myostatin inhibitors.

S5. Diuretics and other masking agents.

Masking agents are prohibited. They include:

Diuretics, probenecid, plasma expanders (e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol) and other substances with similar biological effect(s).

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone and topical dorzolamide and brinzolamide, which are not prohibited).

[Comment to class S5:

A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic in association with threshold or sub-threshold levels of an exogenous Prohibited Substance(s).]

Prohibited methods

M1. Enhancement of oxygen transfer

The following are prohibited:

  • 1.

    Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin.

  • 2.

    Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products).

M2. Chemical and physical manipulation

  • 1.

    Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration.

  • 2.

    Intravenous infusions are prohibited except in the management of surgical procedures, medical emergencies or clinical investigations.

M3. Gene doping

The transfer of cells or genetic elements or the use of cells, genetic elements or pharmacological agents to modulating expression of endogenous genes having the capacity to enhance athletic performance, is prohibited.

Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited.

Substances and methods prohibited in-competition

In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:

Prohibited substances

S6. Stimulants

All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2009 Monitoring Program3)The following substances included in the 2009 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances. .

Stimulants include:

  • a.

    Non Specified Stimulants:

    Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(D-); methylenedioxyamphetamine; methylenedioxymethamphetamine; p-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prolintane.

    A stimulant not expressly listed in this section is a Specified Substance.

  • b.

    Specified Stimulants (examples):

    Adrenaline4)Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. ; cathine5)Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. ; ephedrine6)Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. ; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamphetamine; meclofenoxate; methylephedrine6)Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.; methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; selegiline; sibutramine; strychnine; tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s).

S7. Narcotics

The following narcotics are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. Cannabinoids

Cannabinoids (e.g. hashish, marijuana) are prohibited.

S9. Glucocorticosteroids

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of use must be completed by the Athlete for glucocorticosteroids administered by intraarticular, periarticular, peritendinous, epidural, intradermal and inhalation routes, except as noted below.

Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited and neither require a Therapeutic Use Exemption nor a declaration of use.

Substances prohibited in particular sports

P1. Alcohol

Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is 0.10 g/L.

  • Aeronautic (FAI)

  • Archery (FITA, IPC)

  • Automobile (FIA)

  • Boules (IPC bowls)

  • Karate (WKF)

  • Modern Pentathlon (UIPM) for disciplines involving shooting

  • Motorcycling (FIM)

  • Ninepin and Tenpin Bowling (FIQ)

  • Powerboating (UIM)

P2. Beta-blockers

Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports.

  • Aeronautic (FAI)

  • Archery (FITA, IPC) (also prohibited Out-of-Competition)

  • Automobile (FIA)

  • Billiards and Snooker (WCBS)

  • Bobsleigh (FIBT)

  • Boules (CMSB, IPC bowls)

  • Bridge (FMB)

  • Curling (WCF)

  • Golf (IGF)

  • Gymnastics (FIG)

  • Motorcycling (FIM)

  • Modern Pentathlon (UIPM) for disciplines involving shooting

  • Ninepin and Tenpin Bowling (FIQ)

  • Powerboating (UIM)

  • Sailing (ISAF) for match race helms only

  • Shooting (ISSF, IPC) (also prohibited Out-of-Competition)

  • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

  • Wrestling (FILA)

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

Annex

II

STANDARDS FOR GRANTING THERAPEUTIC USE EXEMPTIONS

Extract from ‘‘INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS’’ of the World Anti-Doping Agency (WADA); in force 1 January 2005

4.0

Criteria for granting a therapeutic use exemption

A Therapeutic Use Exemption (TUE) may be granted to anAthlete permitting the use of a Prohibited Substance or Prohibited Method contained in theProhibited List. An application for a TUE will be reviewed by a Therapeutic Use Exemption Committee (TUEC). TheTUEC will be appointed by an Anti-Doping Organization. An exemption will be granted only in strict accordance with the following criteria:

[Comment: This standard applies to all Athletes as defined by and subject to the Code i.e. able-bodied athletes and athletes with disabilities. This Standard will be applied according to an individual’s circumstances. For example, an exemption that is appropriate for an athlete with a disability may be inappropriate for other athletes.]

  • 4.1.

     The Athlete should submit an application for aTUE no less than 21 days before participating in anEvent.

  • 4.2.

     The Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method were to be withheld in the course of treating an acute or chronic medical condition.

  • 4.3.

     The therapeutic use of the Prohibited Substance orProhibited Method would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. The use of any Prohibited Substance orProhibited Method to increase ‘‘low-normal’’ levels of any endogenous hormone is not considered an acceptable therapeutic intervention.

  • 4.4

    There is no reasonable therapeutic alternative to the use of the otherwise Prohibited Substance or Prohibited Method.

  • 4.5

    The necessity for the use of the otherwise Prohibited Substance or Prohibited Method cannot be a consequence, wholly or in part, of prior non-therapeutic use of any substance from the Prohibited List.

  • 4.6

     The TUE will be cancelled by the granting body, if

    • a)

      the Athlete does not promptly comply with any requirements or conditions imposed by the Anti-Doping Organizationgranting the exemption;

    • b)

      the term for which the TUE was granted has expired;

    • c)

      the Athlete is advised that the TUE has been withdrawn by the Anti-Doping Organization.

    [Comment: Each TUE will have a specified duration as decided upon by the TUEC. There may be cases when a TUE has expired or has been withdrawn and the Prohibited Substance subject to the TUE is still present in the Athlete’s body. In such cases, the Anti-Doping Organization conducting the initial review of an adverse finding will consider whether the finding is consistent with expiry or withdrawal of the TUE.]

  • 4.7. 

    An application for a TUE will not be considered for retroactive approval except in cases where:

    • a)

      emergency treatment or treatment of an acute medical condition was necessary; or

    • b)

      due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to consider, an application prior to Doping Control.

    [Comment: Medical Emergencies or acute medical situations requiring administration of an otherwise Prohibited Substance or Prohibited Method before an application for a TUE can be made, are uncommon. Similarly, circumstances requiring expedited consideration of an application for a TUE due to imminent competition are infrequent. Anti-Doping Organizations granting TUEs should have internal procedures which permit such situations to be addressed.]

5.0

Confidentiality of information

  • 5.1.

    The applicant must provide written consent for the transmission of all information pertaining to the application to members of theTUEC and, as required, other independent medical or scientific experts, or to all necessary staff involved in the management, review or appeal of TUEs.

    Should the assistance of external, independent experts be required, all details of the application will be circulated without identifying the Athlete [and physician(s)]Deze woorden zijn door de redactie van het Tractatenblad toegevoegd.involved in the Athlete’s care. The applicant must also provide written consent for the decisions of the TUEC to be distributed to other relevant Anti-Doping Organizationsunder the provisions of the Code.

  • 5.2.

     The members of the TUECs and the administration of the Anti-Doping Organization involved will conduct all of their activities in strict confidence. All members of a TUECand all staff involved will sign confidentiality agreements. In particular they will keep the following information confidential:

    • a)

      all medical information and data provided by the Athlete and physician(s) involved in the Athlete’s care;

    • b)

      all details of the application including the name of the physician(s) involved in the process.

      Should the Athlete wish to revoke the right of theTUEC or the WADA TUEC to obtain any health information on his/her behalf, the Athlete must notify his/her medical practitioner in writing of the fact. As a consequence of such a decision, the Athlete will not receive approval for a TUE or renewal of an existing TUE.

6.0

Therapeutic use exemption committees (TUECs)

TUECs shall be constituted and act in accordance with the following guidelines:

  • 6.1.

    TUECs should include at least three physicians with experience in the care and treatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. In order to ensure a level of independence of decisions, a majority of the members of theTUEC should not have any official responsibility in theAnti-Doping Organization. All members of a TUECwill sign a conflict of interest agreement. In applications involvingAthletes with disabilities, at least one TUECmember must possess specific experience with the care and treatment ofAthletes with disabilities.

  • 6.2.

    TUECs may seek whatever medical or scientific expertise they deem appropriate in reviewing the circumstances of any application for a TUE.

  • 6.3.

     The WADA TUEC shall be composed following the criteria set out in Article 6.1. The WADA TUECis established to review on its own initiative TUE decisions granted by Anti-Doping Organizations. As specified in Article 4.4 of the Code, theWADA TUEC, upon request by Athletes who have been denied TUEs by an Anti-Doping Organization will review such decisions with the power to reverse them.

7.0

Therapeutic use exemption (TUE) application process

  • 7.1.

     A TUE will only be considered following the receipt of a completed application form that must include all relevant documents (see Appendix 1 – TUE form). The application process must be dealt with in accordance with the principles of strict medical confidentiality.

  • 7.2.

     The TUE application form(s), as set out in Appendix 1, can be modified by Anti-Doping Organizations to include additional requests for information, but no sections or items shall be removed.

  • 7.3.

    The TUE application form(s) may be translated into other language(s) by Anti-Doping Organizations, but English or French must remain on the application form(s).

  • 7.4.

     An Athlete may not apply to more than oneAnti-Doping Organization for a TUE. The application must identify the Athlete’s sport and, where appropriate, discipline and specific position or role.

  • 7.5.

    The application must list any previous and/or current requests for permission to use an otherwise Prohibited Substance orProhibited Method, the body to whom that request was made, and the decision of that body.

  • 7.6.

     The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application.

  • 7.7.

    Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the Anti-Doping Organization will be undertaken at the expense of the applicant or his/her national sport governing body.

  • 7.8.

     The application must include a statement by an appropriately qualified physician attesting to the necessity of the otherwiseProhibited Substance or Prohibited Method in the treatment of the Athlete and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.

  • 7.9.

     The dose, frequency, route and duration of administration of the otherwise Prohibited Substance or Prohibited Method in question must be specified.

  • 7.10.

     Decisions of the TUEC, should be completed within 30 days of receipt of all relevant documentation and will be conveyed in writing to the Athlete by the relevant Anti-Doping Organization. Where a TUE has been granted to anAthlete in the Anti-Doping Organization Registered Testing Pool, the Athlete and WADA will be provided promptly with an approval which includes information pertaining to the duration of the exemption and any conditions associated with the TUE.

  • 7.11.
    • a)

      Upon receiving a request by an Athlete for review, as specified in Article 4.4. of the Code, theWADA TUEC will, as specified in Article 4.4 of theCode, be able to reverse a decision on a TUEgranted by an Anti-Doping Organization. TheAthlete shall provide to the WADA TUECall the information for a TUE as submitted initially to theAnti-Doping Organization accompanied by an application fee. Until the review process has been completed, the original decision remains in effect. The process should not take longer than 30 days following receipt of the information by WADA.

    • b)

      WADA can undertake a review at any time. TheWADA TUEC will complete its review within 30 days.

  • 7.12.

     If the decision regarding the granting of a TUEis reversed on review, the reversal shall not apply retroactively and shall not disqualify the Athlete’s results during the period that the TUE had been granted and shall take effect no later than 14 days following notification of the decision to theAthlete.

8.0

 Abbreviated therapeutic use exemption (ATUE) application process

  • 8.1.

     It is acknowledged that some substances included on theList of Prohibited Substances are used to treat medical conditions frequently encountered in the Athlete population. In such cases, a full application as detailed in section 4 and section 7 is unnecessary. Accordingly an abbreviated process of theTUE is established.

  • 8.2.

     The Prohibited Substances or Prohibited Methods which may be permitted by this abbreviated process are strictly limited to the following:

    Beta-2 agonists (formoterol, salbutamol, salmeterol and terbutaline) by inhalation, and glucocorticosteroids by non-systemic routes.

  • 8.3.

    To use one of the substances above, the Athleteshall provide to the Anti-Doping Organization a medical notification justifying the therapeutic necessity. Such medical notification, as contained in Appendix 2, shall describe the diagnosis, name of the drug, dosage, route of administration and duration of the treatment. When applicable any tests undertaken in order to establish the diagnosis should be included (without the actual results or details).

  • 8.4.

     The abbreviated process includes:

    • a)

      approval for use of Prohibited Substances subject to the abbreviated process is effective upon receipt of a complete notification by the Anti-Doping Organization. Incomplete notifications must be returned to the applicant;

    • b)

      on receipt of a complete notification, the Anti-Doping Organization shall promptly advise the Athlete. As appropriate, the Athlete’s IF, NF and NADO shall also be advised. The Anti-Doping Organization shall advise WADA only upon receipt of a notification from an International-level Athlete;

    • c)

      a notification for an ATUE will not be considered for retroactive approval except:

      • -

         if emergency treatment or treatment of an acute medical condition was necessary; or

      • -

         due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to receive, an application prior to Doping Control.

  • 8.5.
    • a)

      A review by the TUEC or theWADA TUEC can be initiated at any time during the duration of an ATUE.

    • b)

      If an Athlete requests a review of a subsequent denial of anATUE, the WADA TUEC will have the ability to request from the Athlete additional medical information as deemed necessary, the expenses of which should be met by the Athlete.

  • 8.6.

     An ATUE may be cancelled by the TUEC orWADA TUEC at any time. The Athlete, his/her IF and all relevant Anti-Doping Organizations shall be notified immediately.

  • 8.7.

    The cancellation shall take effect immediately following notification of the decision to the Athlete. TheAthlete will nevertheless be able to apply under section 7 for a TUE.

9.0

 Clearing house

  • 9.1.

    Anti-Doping Organizations are required to provideWADA with all TUEs, and all supporting documentation, issued under section 7.

  • 9.2.

     With respect to ATUEs, Anti-Doping Organizations shall provide WADA with medical applications submitted by International-level Athletesissued under section 8.4.

  • 9.3.

     The Clearing house shall guarantee strict confidentiality of all the medical information.

Internationaal Verdrag tegen doping in de sport

Preambule

De Algemene Conferentie van de Organisatie van de Verenigde Naties voor Onderwijs, Wetenschap en Cultuur, hierna aangeduid als UNESCO, bijeengekomen te Parijs van 3 tot en met 21 oktober 2005 tijdens haar 33e zitting,

Overwegend dat het doel van UNESCO is een bijdrage te leveren aan vrede en veiligheid door samenwerking tussen naties te bevorderen door middel van onderwijs, wetenschap en cultuur,

Verwijzend naar bestaande internationale instrumenten inzake mensenrechten,

Zich bewust van resolutie 58/5 aangenomen door de Algemene Vergadering van de Verenigde Naties op 3 november 2003, betreffende sport als middel om onderwijs, gezondheid, ontwikkeling en vrede te bevorderen, en met name paragraaf 7 daarvan,

Zich er tevens van bewust dat sport een belangrijke rol dient te spelen bij de bescherming van de gezondheid, bij morele en culturele vorming en lichamelijke opvoeding en bij het bevorderen van wederzijds begrip en vrede in de wereld,

Gelet op de noodzaak internationale samenwerking gericht op het uitbannen van doping in de sport te bevorderen en te coördineren,

Bezorgd over het gebruik door sporters van dopingmiddelen in de sport en de gevolgen daarvan voor hun gezondheid, het beginsel van fair play, het uitbannen van bedrog en de toekomst van de sport,

Indachtig het feit dat doping een bedreiging vormt voor de ethische beginselen en educatieve waarden vervat in het Internationale Handvest voor Lichamelijke Opvoeding en Sport van UNESCO en in het Olympisch Handvest,

In herinnering roepend dat de Overeenkomst ter bestrijding van doping en het Aanvullend Protocol daarbij aangenomen in het kader van de Raad van Europa instrumenten van internationaal publiekrecht zijn, die ten grondslag liggen aan nationaal antidopingbeleid en aan intergouvernementele samenwerking,

Herinnerend aan de Aanbevelingen inzake doping aangenomen tijdens de tweede, derde en vierde Internationale Conferentie van ministers en hoge ambtenaren verantwoordelijk voor lichamelijke opvoeding en sport, door UNESCO georganiseerd te Moskou (1988), Punta del Este (1999) en Athene (2004) en aan 32 C/Resolutie 9 aangenomen door de Algemene Conferentie van UNESCO tijdens haar 32e zitting (2003),

Indachtig de Wereldantidopingcode aangenomen door het Mondiaal Antidopingagentschap tijdens de Wereldconferentie inzake doping in de sport, Kopenhagen, 5 maart 2003 en de Verklaring van Kopenhagen tegen het gebruik van doping in de sport,

Tevens indachtig de invloed die topsporters hebben op de jeugd,

Zich bewust van de permanente behoefte onderzoek uit te voeren en te bevorderen met als doel het verbeteren van de detectie van doping en een beter begrip van de factoren die van invloed zijn op het gebruik ervan teneinde tot zo doeltreffend mogelijke preventiestrategieën te komen,

Zich tevens bewust van het belang van voortdurende educatie van sporters, hun begeleiders en de maatschappij in het algemeen op het gebied van het voorkomen van doping,

Indachtig de noodzaak de capaciteit van Staten die Partij zijn om antidopingprogramma’s te implementeren op te bouwen,

Zich ervan bewust dat overheidsinstanties en sportorganisaties elkaar aanvullende verantwoordelijkheden hebben bij het voorkomen en bestrijden van doping in de sport, in het bijzonder het goede verloop, op basis van het beginsel van fair play, van sportevenementen, en bij het beschermen van de gezondheid van de deelnemers daaraan,

Erkennend dat deze autoriteiten en organisaties daartoe dienen samen te werken en daarbij de hoogste mate van onafhankelijkheid en transparantie op alle van toepassing zijnde niveaus dienen te waarborgen,

Vastbesloten nadere maatregelen te nemen, in hechtere samenwerking, gericht op de uitbanning van doping in de sport,

Erkennend dat de uitbanning van doping in de sport ten dele afhankelijk is van de verdere harmonisatie van normen en praktijken op het gebied van de bestrijding van doping in de sport en samenwerking op nationaal en mondiaal niveau,

Neemt dit Verdrag aan op 19 oktober 2005.

DEEL

I

REIKWIJDTE

Artikel

1

Doelstelling van het Verdrag

De doelstelling van dit Verdrag, in het kader van de strategie en het activiteitenprogramma van UNESCO op het gebied van lichamelijke opvoeding en sport, is het bevorderen van het voorkomen en bestrijden van doping in de sport, met het oog op de uitbanning ervan.

Artikel

2

Begripsomschrijvingen

Deze begripsomschrijvingen dienen begrepen te worden in de context van de Wereldantidopingcode. Indien de bepalingen daarvan in strijd zijn met die van het Verdrag, zijn de bepalingen van het Verdrag doorslaggevend.

Voor de toepassing van dit Verdrag wordt verstaan onder:

  • 1.

    „Geaccrediteerde dopingcontrolelaboratoria’’ door het Mondiaal Antidopingagentschap geaccrediteerde laboratoria.

  • 2.

    „Antidopingorganisatie’’ een orgaan dat verantwoordelijk is voor het aannemen van regels voor het in gang zetten, implementeren of handhaven van elk deel van het proces van dopingcontrole. Hieronder worden onder andere begrepen het Internationaal Olympisch Comité, het Internationaal Paralympisch Comité, andere organisatoren van grote evenementen die tijdens hun evenementen dopingcontroles uitvoeren, het Mondiaal Antidopingagentschap, internationale sportbonden en nationale antidopingorganisaties.

  • 3.

    „Schending van het antidopingreglement’’ in de sport een of meer van de onderstaande schendingen:

    • a)

      de aanwezigheid van een verboden stof of een van haar metabolieten of markers in een lichaamsweefsel of lichaamsvloeistof van een sporter;

    • b)

      gebruik of poging tot gebruik van een verboden stof of een verboden methode;

    • c)

      weigering een monster af te staan na aankondiging zoals toegestaan door het toepasselijke antidopingreglement, of het nalaten hiervan zonder dwingende reden, of het anderszins vermijden van het afstaan van monsters;

    • d)

      schending van de toepasselijke vereisten inzake de beschikbaarheid van sporters voor controles buiten wedstrijdverband met inbegrip van het verzuimen de vereiste informatie over de verblijfplaats te verstrekken en het missen van controles waarvan verklaard wordt dat zij zijn gebaseerd op redelijke regelgeving;

    • e)

      manipuleren, of poging tot het manipuleren, van een onderdeel van een dopingcontrole;

    • f)

      bezit van verboden stoffen of methoden;

    • g)

      handel in een verboden stof of een verboden methode;

    • h)

      toediening of poging tot toediening van een verboden stof of verboden methode aan een sporter, of hulp bij, aanmoediging van, medeplichtigheid aan, uitlokking van, verhulling van of enige andere vorm van medeplichtigheid aan een schending of poging tot schending van een antidopingreglement.

  • 4.

    „Sporter’’, ten behoeve van dopingcontrole, elke persoon die een sport beoefent op internationaal of nationaal niveau zoals omschreven door elke nationale antidopingorganisatie en door de Staten die Partij zijn aanvaard en elke andere persoon die een sport beoefent of aan een evenement deelneemt op een lager niveau dat door de Staten die Partij zijn is aanvaard. Ten behoeve van opleidings- en trainingsprogramma’s wordt onder „sporter’’ verstaan elke persoon die een sport beoefent die onder toezicht van een sportorganisatie staat.

  • 5.

    „Begeleiders van sporters’’ coaches, trainers, managers, zaakwaarnemers, teammedewerkers, officials, medisch of paramedisch personeel met wie een sporter die deelneemt aan of zich voorbereidt op deelname aan een sportwedstrijd samenwerkt of door wie deze wordt behandeld.

  • 6.

    „Code’’ de Wereldantidopingcode aangenomen door het Mondiaal Antidopingagentschap op 5 maart 2003 te Kopenhagen, die als Aanhangsel 1 bij dit Verdrag is gevoegd.

  • 7.

    „Wedstrijd’’ een enkele race, match, partij of afzonderlijke sportieve krachtmeting.

  • 8.

    „Dopingcontrole’’ het volledige proces met inbegrip van het plannen van uit te voeren controles, verzamelen en hanteren van monsters, laboratoriumonderzoek, resultatenbeheer, hoorzittingen en beroepsprocedures.

  • 9.

    „Doping in de sport’’ het zich voordoen van een schending van het antidopingreglement.

  • 10.

    „Naar behoren gemachtigde dopingcontroleteams’’ dopingcontroleteams die onder de bevoegdheid van internationale of nationale antidopingorganisaties opereren.

  • 11.

    Controle „binnen wedstrijdverband’’ ten behoeve van het onderscheid tussen controles binnen wedstrijdverband en buiten wedstrijdverband, tenzij anderszins voorzien in het reglement van een internationale sportbond of andere relevante antidopingorganisatie, een controle waarbij een sporter voor controle wordt aangewezen in verband met een specifieke wedstrijd.

  • 12.

    „Internationale norm voor laboratoria’’ de norm die als Aanhangsel 2 bij dit Verdrag is gevoegd.

  • 13.

    „Internationale norm voor dopingcontroles’’ de norm die als Aanhangsel 3 bij dit Verdrag is gevoegd.

  • 14.

    „Onaangekondigd’’ een dopingcontrole die plaatsvindt zonder dat de sporter daarvan vooraf op de hoogte wordt gesteld en waarbij de sporter voordurend door een controleur wordt vergezeld vanaf het moment van de aankondiging tot en met de afname van het monster.

  • 15.

    „Onaangekondigd’’ een dopingcontrole die plaatsvindt zonder dat de sporter daarvan vooraf op de hoogte wordt gesteld en waarbij de sporter voordurend door een controleur wordt vergezeld vanaf het moment van de aankondiging tot en met de afname van het monster.

  • 16.

    Dopingcontrole „buiten wedstrijdverband’’ elke dopingcontrole die niet binnen wedstrijdverband plaatsvindt.

  • 17.

    „Lijst van verboden stoffen en methoden’’ de lijst vervat in Bijlage I bij dit Verdrag waarin de verboden stoffen en verboden methoden vermeld staan.

  • 18.

    „Verboden methode’’ elke methode die als zodanig omschreven staat in de Lijst van verboden stoffen en methoden vervat in Bijlage I bij dit Verdrag.

  • 19.

    „Verboden stof’’ elke stof die als zodanig omschreven staat in de Lijst van verboden stoffen en methoden vervat in Bijlage I bij dit Verdrag.

  • 20.

    „Sportorganisatie’’ elke organisatie die de eindverantwoordelijkheid draagt voor een evenement met een of meer sporten.

  • 21.

    „Normen voor het verlenen van dispensatie voor therapeutisch gebruik’’ de normen vervat in Bijlage II bij dit Verdrag.

  • 22.

    „Controle’’ de onderdelen van het dopingcontroleproces inhoudende het plannen van de controles, het verzamelen en hanteren van monsters en het verzenden van monsters naar het laboratorium.

  • 23.

    „Dispensatie voor therapeutisch gebruik’’ een dispensatie verleend in overeenstemming met de normen voor het verlenen van dispensatie voor therapeutisch gebruik.

  • 24.

    „Gebruik’’ het aanbrengen, innemen, injecteren of op welke wijze dan ook consumeren van een verboden stof of verboden methode.

  • 25.

    „Mondiaal Antidopingagentschap (WADA)’’ de stichting die op 10 november 1999 onder deze naam werd opgericht naar Zwitsers recht.

Artikel

3

Middelen om het doel van het Verdrag te verwezenlijken

Ter verwezenlijking van het doel van het Verdrag verplichten de Staten die Partij zijn zich tot het:

  • a.

    invoeren van passende maatregelen op nationaal en internationaal niveau die verenigbaar zijn met de beginselen van de Code;

  • b.

    aanmoedigen van alle vormen van internationale samenwerking gericht op het beschermen van de sporters en de ethiek in de sport en op het delen van onderzoeksresultaten;

  • c.

    bevorderen van internationale samenwerking tussen de Staten die Partij zijn en organisaties die een leidende rol hebben bij de bestrijding van doping in de sport, met name Mondiaal Antidopingagentschap.

Artikel

4

Verhouding van het Verdrag tot de Code

Artikel

5

Maatregelen om de doelstellingen van dit Verdrag te verwezenlijken

Door de in dit Verdrag vervatte verplichtingen te eerbiedigen, verplicht elke Staat die Partij is zich passende maatregelen in te voeren. Dergelijke maatregelen kunnen wetgeving, regulering, beleid of administratieve praktijken inhouden.

Artikel

6

Verhouding tot andere internationale instrumenten

Dit Verdrag heeft geen verandering tot gevolg van de rechten en verplichtingen van Staten die Partij zijn die voortvloeien uit eerder gesloten verdragen die verenigbaar zijn met het onderwerp en het doel van dit Verdrag. Dit doet geen afbreuk aan het genot van hun rechten door andere Staten die Partij zijn of de nakoming van hun verplichtingen uit hoofde van dit Verdrag.

DEEL

II

ANTIDOPINGACTIVITEITEN OP NATIONAAL NIVEAU

Artikel

7

Coördinatie op nationaal niveau

De Staten die Partij zijn, waarborgen de toepassing van dit Verdrag in het bijzonder door coördinatie op nationaal niveau. Teneinde hun verplichtingen ingevolge dit Verdrag na te komen, kunnen de Staten die Partij zijn zich verlaten op antidopingorganisaties alsmede op sportautoriteiten en -organisaties.

Artikel

8

Beperking van de beschikbaarheid en het gebruik in de sport van verboden stoffen en methoden

Artikel

9

Maatregelen tegen begeleiders van sporters

De Staten die Partij zijn, nemen zelf maatregelen, met inbegrip van sancties of straffen, tegen begeleiders van sporters die het antidopingreglement schenden of een ander strafbaar feit met betrekking tot doping in de sport begaan, of moedigen sportorganisaties of antidopingorganisaties aan zulks te doen.

Artikel

10

Voedingssupplementen

De Staten die Partij zijn, moedigen, wanneer van toepassing, producenten en distributeurs van voedingssupplementen aan beste praktijken in te stellen op het gebied van marketing en distributie van voedingssupplementen, met inbegrip van informatie over hun analytische samenstelling en kwaliteitsborging.

Artikel

11

Financiële maatregelen

De Staten die Partij zijn,

  • a)

    stellen, wanneer van toepassing, binnen hun respectieve begrotingen fondsen beschikbaar ter ondersteuning van een nationaal dopingcontroleprogramma in alle takken van sport of ondersteunen sportorganisaties en antidopingorganisaties bij het financieren van dopingcontroles, hetzij door hun daarvoor rechtstreeks subsidies of toelagen toe te kennen, hetzij door met de kosten van dergelijke controles rekening te houden bij het vaststellen van de subsidies of toelagen die aan deze organisaties worden toegekend;

  • b)

    nemen, wanneer van toepassing, stappen om de op de sport betrekking hebbende financiële ondersteuning in te trekken voor individuele sporters of begeleiders van sporters die geschorst zijn na een schending van een antidopingreglement, gedurende de periode waarin zij geschorst zijn;

  • c)

    trekken, wanneer van toepassing, een gedeelte van of de volledige financiële steun of andere op de sport betrekking hebbende steun in voor elke sportorganisatie of antidopingorganisatie die zich niet aan de Code of het ingevolge de Code aangenomen antidopingreglement houdt.

Artikel

12

Maatregelen om dopingcontrole te vergemakkelijken

De Staten die Partij zijn,

  • a.

    bevorderen en vergemakkelijken, wanneer van toepassing, het uitvoeren van dopingcontroles door de sportorganisaties en antidopingorganisaties onder hun rechtsmacht op een wijze die verenigbaar is met de Code, met inbegrip van controles die onaangekondigd, buiten en binnen wedstrijdverband plaatsvinden;

  • b.

    bevorderen en vergemakkelijken, wanneer van toepassing, onderhandelingen door sportorganisaties en antidopingorganisaties over overeenkomsten uit hoofde waarvan het wordt toegestaan hun leden te laten controleren door naar behoren bevoegde dopingcontroleteams uit andere landen;

  • c.

    verplichten zich, wanneer van toepassing, de sportorganisaties en antidopingorganisaties onder hun rechtsmacht te helpen toegang te krijgen tot een geaccrediteerd dopingcontrolelaboratorium ten behoeve van de analyse van afgenomen monsters.

DEEL

III

INTERNATIONALE SAMENWERKING

Artikel

13

Samenwerking tussen antidopingorganisaties en sportorganisaties

De Staten die Partij zijn, bevorderen de samenwerking tussen antidopingorganisaties, overheidsinstanties en sportorganisaties onder hun rechtsmacht en die onder de rechtsmacht van andere Staten die Partij zijn, teneinde, op internationaal niveau, de doelstellingen van dit Verdrag te verwezenlijken.

Artikel

14

Ondersteuning van de missie van het Mondiaal Antidopingagentschap

De Staten die Partij zijn, verplichten zich de belangrijke missie van het Mondiaal Antidopingagentschap in de internationale dopingbestrijding te ondersteunen.

Artikel

15

Evenredige financiering van het Mondiaal Antidopingagentschap

De Staten die Partij zijn, ondersteunen het beginsel van evenredige financiering van de goedgekeurde jaarlijkse basisbegroting van het Mondiaal Antidopingagentschap door overheidsinstanties en de Olympische Beweging.

Artikel

16

Internationale samenwerking bij dopingcontrole

Erkennend dat de bestrijding van doping in de sport slechts doeltreffend kan zijn wanneer sporters onaangekondigd kunnen worden gecontroleerd en de monsters tijdig voor analyse naar laboratoria kunnen worden verzonden, nemen de Staten die Partij zijn, wanneer van toepassing en in overeenstemming met hun nationale wetgeving en procedures, de volgende maatregelen:

  • a.

    vergemakkelijken van de taak van het Mondiaal Antidopingagentschap en antidopingorganisaties die overeenkomstig de Code werken, met inachtneming van de relevante regelgeving van de gastheerlanden, om binnen en buiten wedstrijdverband hun sporters op het gebruik van doping te controleren, hetzij op hun grondgebied, hetzij elders;

  • b.

    vergemakkelijken van de tijdige grenspassage van naar behoren gemachtigde dopingcontroleteams wanneer zij dopingcontroleactiviteiten uitvoeren;

  • c.

    samenwerking ter bespoediging van de tijdige verzending of grenspassage van monsters op zodanige wijze dat de veiligheid en integriteit daarvan behouden blijven;

  • d.

    ondersteuning van de internationale coördinatie van dopingcontroles door verschillende antidopingorganisaties en samenwerking daartoe met het Mondiaal Antidopingagentschap;

  • e.

    bevorderen van de samenwerking tussen dopingcontrolelaboratoria onder hun rechtsmacht en laboratoria onder de rechtsmacht van andere Staten die Partij zijn. In het bijzonder dienen Staten die Partij zijn met geaccrediteerde dopingcontrolelaboratoria laboratoria onder hun rechtsmacht aan te moedigen samen te werken met andere Staten die Partij zijn opdat deze de ervaring, vaardigheden en technieken kunnen verwerven die nodig zijn om eigen laboratoria op te richten indien zij dit zouden wensen;

  • f.

    bevorderen en ondersteunen van wederzijdse controleregelingen tussen aangewezen antidopingorganisaties, in overeenstemming met de Code;

  • g.

    wederzijdse erkenning van de dopingcontroleprocedures en het resultatenbeheer van elke antidopingorganisatie, met inbegrip van de daaruit voortvloeiende sancties op sportgebied, die in overeenstemming zijn met de Code.

Artikel

17

Vrijwillig Fonds

Artikel

18

Inzet en bestuur van het Vrijwillig Fonds

Middelen van het Vrijwillig Fonds worden door de Conferentie van Partijen toegewezen ten behoeve van de financiering van door hen goedgekeurde activiteiten, in het bijzonder het ondersteunen van Staten die Partij zijn bij het ontwikkelen en implementeren van antidopingprogramma’s, in overeenstemming met de bepalingen van dit Verdrag, daarbij rekening houdend met de doelstelling van het Mondiaal Antidopingagentschap, en kunnen worden ingezet om de operationele kosten van dit Verdrag te dekken. Aan bijdragen aan het Vrijwillig Fonds mogen geen politieke, economische of andere voorwaarden verbonden worden.

DEEL

IV

VOORLICHTING EN TRAINING

Artikel

19

Algemene beginselen inzake voorlichting en training

Artikel

20

Professionele gedragscodes

De Staten die Partij zijn, moedigen relevante bevoegde sportbonden en -instellingen aan passende gedragscodes, goede praktijken en ethische normen inzake de bestrijding van doping in de sport die in overeenstemming zijn met de Code te ontwikkelen en te implementeren.

Artikel

21

Betrokkenheid van sporters en begeleiders van sporters

De Staten die Partij zijn, bevorderen en ondersteunen, binnen hun mogelijkheden, de actieve betrokkenheid van sporters en begeleiders van sporters bij alle facetten van dopingbestrijding door sportorganisaties en andere relevante organisaties en moedigen sportorganisaties onder hun rechtsmacht aan hetzelfde te doen.

Artikel

22

Sportorganisaties en permanente voorlichting en training op het gebied van dopingbestrijding

De Staten die Partij zijn, moedigen sportorganisaties en antidopingorganisaties aan permanente voorlichtings- en trainingsprogramma’s te implementeren voor alle sporters en begeleiders van sporters inzake de in artikel 19 genoemde gebieden.

Artikel

23

Samenwerking bij voorlichting en training

De Staten die Partij zijn, werken met elkaar en met de relevante organisaties samen om, wanneer van toepassing, informatie, expertise en ervaringen met betrekking tot doeltreffende programma’s om doping te bestrijden uit te wisselen.

DEEL

V

ONDERZOEK

Artikel

24

Bevorderen van onderzoek naar dopingbestrijding

De Staten die Partij zijn, verplichten zich, binnen hun mogelijkheden, onderzoek naar dopingbestrijding in samenwerking met sportorganisaties en andere organisaties aan te moedigen en te bevorderen met betrekking tot:

  • a.

    manieren en methoden om wetenschappelijk verantwoorde fysiologische en psychologische trainingsprogramma’s op te stellen die de integriteit van de betrokken persoon eerbiedigen;

  • b.

    manieren en methoden om wetenschappelijk verantwoorde fysiologische en psychologische trainingsprogramma’s op te stellen die de integriteit van de betrokken persoon eerbiedigen;

  • c.

    het gebruik van alle nieuwe stoffen en methoden die uit wetenschappelijke ontwikkelingen resulteren.

Artikel

25

De aard van onderzoek ten behoeve van dopingbestrijding

Bij het bevorderen van onderzoek ten behoeve van dopingbestrijding, als vervat in artikel 24, waarborgen de Staten die Partij zijn dat dergelijk onderzoek:

  • a.

    voldoet aan internationaal erkende ethische praktijken;

  • b.

    niet de toediening aan sporters van verboden stoffen en methoden inhoudt;

  • c.

    uitsluitend wordt uitgevoerd na instelling van adequate voorzorgsmaatregelen teneinde te voorkomen dat de resultaten van onderzoek ten behoeve van dopingbestrijding worden misbruikt en voor dopingdoeleinden worden toegepast.

Artikel

26

Delen van de resultaten van onderzoek ten behoeve van dopingbestrijding

Met inachtneming van het toepasselijke nationaal en internationaal recht, delen de Staten die Partij zijn, wanneer van toepassing, de resultaten van beschikbaar onderzoek ten behoeve van dopingbestrijding met de andere Staten die Partij zijn en met het Mondiaal Antidopingsagentschap.

Artikel

27

Sportwetenschappelijk onderzoek

De Staten die Partij zijn, moedigen:

  • a.

    de wetenschappelijke en medische wereld aan sportwetenschappelijk onderzoek uit te voeren in overeenstemming met de beginselen van de Code;

  • b.

    sportorganisaties en begeleiders van sporters onder hun rechtsmacht aan sportwetenschappelijk onderzoek te implementeren dat verenigbaar is met de beginselen van de Code.

DEEL

VI

TOEZICHT OP HET VERDRAG

Artikel

28

Conferentie van Partijen

Artikel

29

Adviesorgaan van en waarnemers bij de Conferentie van Partijen

Het Mondiaal Antidopingagentschap wordt uitgenodigd als adviesorgaan van de Conferentie van Partijen. Het Internationaal Olympisch Comité, het Internationaal Paralympisch Comité, de Raad van Europa en het Intergovernmental Committee for Physical Education and Sport (CIGEPS) worden als waarnemers uitgenodigd. De Conferentie van Partijen kan besluiten andere relevante organisaties als waarnemers uit te nodigen.

Artikel

30

Taken van de Conferentie van Partijen

Artikel

31

Nationale verslagen aan de Conferentie van Partijen

De Staten die Partij zijn, zenden de Conferentie van Partijen elke twee jaar via het Secretariaat, in een van de officiële talen van UNESCO, alle relevante informatie toe betreffende door hen getroffen maatregelen te behoeve van de naleving van de bepalingen van dit Verdrag.

Artikel

32

Secretariaat van de Conferentie van Partijen

Artikel

33

Wijzigingen

Artikel

34

Specifieke wijzigingsprocedure voor de Bijlagen bij het Verdrag

DEEL

VII

SLOTBEPALINGEN

Artikel

35

Federale of niet-unitaire constitutionele stelsels

De volgende bepalingen zijn van toepassing op Staten die Partij zijn met een federaal of niet-unitair constitutioneel systeem:

  • a.

    Ten aanzien van de bepalingen van dit Verdrag, waarvan de implementatie onder de rechtsmacht van de federale of centrale wetgevende macht valt, zijn de verplichtingen van de federale of centrale regering dezelfde als die voor Staten die Partij zijn die geen federale staten zijn;

  • b.

    Ten aanzien van de bepalingen van dit Verdrag, waarvan de implementatie onder de rechtsmacht valt van de afzonderlijke Staten, landen, provincies of kantons die door het constitutionele stelsel van de federatie niet verplicht zijn wetgevende maatregelen te treffen, stelt de federale regering de bevoegde autoriteiten van dergelijke Staten, landen, provincies of kantons in kennis van genoemde bepalingen, tezamen met haar aanbeveling deze aan te nemen.

Artikel

36

Bekrachtiging, aanvaarding, goedkeuring of toetreding

Dit Verdrag dient te worden bekrachtigd, aanvaard, goedgekeurd of hiertoe dient te worden toegetreden door de lidstaten van UNESCO in overeenstemming met hun onderscheiden grondwettelijke procedures. De akten van bekrachtiging, aanvaarding, goedkeuring of toetreding dienen te worden nedergelegd bij de Directeur-Generaal van UNESCO.

Artikel

37

Inwerkingtreding

Artikel

38

Uitbreiding tot andere gebieden van het Verdrag

Artikel

39

Opzegging

Elke Staat die Partij is, kan dit Verdrag opzeggen. De opzegging wordt door middel van een schriftelijke akte ter kennis gebracht en bij de Directeur-Generaal van UNESCO nedergelegd. De opzegging wordt van kracht op de eerste dag van de maand die volgt op het verstrijken van een tijdvak van zes maanden na ontvangst van de akte van opzegging. Dit heeft in geen geval gevolgen voor de financiële verplichtingen van de desbetreffende Staat die Partij is tot de datum waarop de opzegging van kracht wordt.

Artikel

40

Depositaris

De Directeur-Generaal van UNESCO is de Depositaris van dit Verdrag en de wijzigingen daarvan. De Directeur-Generaal van UNESCO stelt als Depositaris alle Staten die Partij zijn bij dit Verdrag alsmede de andere lidstaten van de Organisatie in kennis van:

  • a.

    de nederlegging van elke akte van bekrachtiging, aanvaarding, goedkeuring of toetreding;

  • b.

    de datum van inwerkingtreding van dit Verdrag overeenkomstig artikel 37;

  • c.

    elk verslag opgesteld uit hoofde van de bepalingen van artikel 31;

  • d.

    elke wijziging van het Verdrag of van de Bijlagen aangenomen in overeenstemming met de bovenstaande artikelen 33 en 34 en de datum waarop de wijziging van kracht wordt;

  • e.

    elke uit hoofde van de bepalingen van artikel 38 gedane verklaring of kennisgeving;

  • f.

    elke uit hoofde van de bepalingen van artikel 39 gedane kennisgeving en de datum waarop de opzegging van kracht wordt;

  • g.

    elke andere akte, kennisgeving of mededeling met betrekking tot dit Verdrag.

Artikel

42

Gezaghebbende teksten

Artikel

43

Voorbehouden

Voorbehouden die onverenigbaar zijn met het onderwerp en het doel van dit Verdrag zijn niet toegestaan.

GEDAAN te Parijs, op 19 oktober 2005, in twee oorspronkelijke exemplaren voorzien van de handtekening van de Voorzitter van de Algemene Conferentie van UNESCO tijdens haar 33e zitting en van de Directeur-Generaal van UNESCO, die zullen worden nedergelegd in het archief van UNESCO.

Bijlage

I

De Lijst van verboden stoffen en methoden - Internationale norm

De tekst van de vertaling is niet beschikbaar.

Bijlage

II

NORM VOOR HET VERLENEN VAN DISPENSATIE VOOR THERAPEUTISCH GEBRUIK

De tekst van de vertaling is niet beschikbaar.